CpG ODN (K3)—toll-like receptor 9 agonist—induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study

CpG ODN (K3)—toll-like receptor 9 agonist—induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study

Background: Cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN) (K3)—a novel synthetic single-stranded DNA immune adjuvant for cancer immunotherapy—induces a potential Th1-type immune response against cancer cells. We conducted a phase I study of CpG ODN (K3) in patients with lung cancer to as...

Full description

Bibliographic Details
Main Authors: Hamaguchi, M. (Author), Hirata, H. (Author), Ishii, K.J (Author), Kida, H. (Author), Kimura, K. (Author), Kumanogoh, A. (Author), Kuroda, E. (Author), Manabe, Y. (Author), Miyake, K. (Author), Mizuno, Y. (Author), Nishida, S. (Author), Otsuka, T. (Author), Shibahara, T. (Author), Shiroyama, T. (Author), Takeda, Y. (Author), Temizoz, B. (Author), Yagita, M. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Cytosine-phosphate-guanine oligodeoxynucleotide
Dose-limiting toxicity
Immunotherapy
Lung cancer
Toll-like receptor 9 agonist
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items